ADCT
ADC Therapeutics SA
$1.28
-0.07 (-5.19%)
At close · Jul 8
Market Cap
$162.80M
Shares
127,191,158
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.28
Open$1.33
Day$1.28–1.37
52W$0.78–4.98
Avg vol 30d2.7M
Short int6.0M · 4.7% float · 1.3d
Short vol43%
Last earningsMay 4, 2026
DataMay 2020–Jul 2026
Filing10-Q · May 4
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−64%
below
Price vs 50-day avg
−47%
below
RSI (14)
37
neutral
MACD trend
Positive
52-week position
12%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+31%
trailing
6-month return
−65%
trailing
YTD return
−64%
this year
Relative strength
−73%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Distributing
1 of 117 funds reported for Jun 30 · net -683 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.72% of float · ▼ -1.0% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
117 holders — near 3-yr high, broad support
Squeeze score
38
low risk · 0–100
Fundamentals
Revenue growth
+15%
Y/Y
EPS growth
+31%
Y/Y
Free cash flow
$-141.4M
Balance sheet
$261.3M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
12.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Jul 31, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 4, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−64%
Bearish
Price vs 50-day avg
−47%
Bearish
RSI (14)
37
Neutral
MACD trend
Positive
Bullish
52-week position
12%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Distributing
1 of 117 funds reported for Jun 30 · net -683 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.72% of float · ▼ -1.0% MoM · 1.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
117 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $1 · 12%
52-wk high $5
vs 200-day avg -64%
vs 50-day avg -47%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss non-GAAP | $19.7M | first quarter of 2026 | — |
| Adjusted net loss per basic and diluted share non-GAAP | $0.13 | first quarter of 2026 | — |
| Total adjusted operating expenses non-GAAP | $42.9M | first quarter of 2026 | — |
| adjusted operating expenses non-GAAP | $42.9M | Q1 2026 call | — |
| Adjusted total operating expenses non-GAAP | $181.3M | Full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADCT
this stock
ADC Therapeutics SA
|
$162.80M | -63.7% | +1.8% | — | 4.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.49B | +7.4% | — | — | 0.2% |
|
GALDY
Galderma Group AG/ADR
|
$51.08B | +5.2% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$42.94B | -3.6% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADCT | +19.6% | +30.9% | -65.4% | +19.6% | -63.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +19.8% | +30.0% | -72.9% | +19.8% | -73.1% |